OBJECTIVE:To develop a new patient-reported outcome measure for progressive supranuclear palsy(PSP)and to test its psychometric properties.METHODS:First,the authors generated a pool of potential scale items from in-depth patient interviews.Second,the authors administered these items,in the form of a questionnaire,to a sample of people with PSP and traditional psychometric methods were used to develop a rating scale satisfying standard criteria for reliability and validity.Third,the authors examined the psychometric properties of the rating scale in a second sample.RESULTS:In stage 1,a pool of 87 items was generated from 27 patient interviews.In stage 2,a scale with two subscales(physical,22 items;mental,23 items),satisfying standard criteria for reliability and validity,was developed from the response data of 225 patients with PSP.In stage 3,the scale was examined in 188 people with PSP.Missing data were low,scores in both subscales were evenly distributed,floor and ceiling effects were small.Reliability was high(Cronbach’s alpha 0.93,0.95;test-retest 0.95,0.92).Validity was supported by the interscale intercorrelation(0.60),factor analysis,and the magnitude and pattern of correlations with four other rating scales,disease severity,and disease duration.The psychometric properties of the new scale were similar in the United Kingdom and North America,and in clinic-and community-based samples studied.CONCLUSIONS:The Progressive Supranuclear Palsy Quality of Life scale(PSP-QoL)may be a helpful patient-reported scale for clinical trials and studies in PSP. OBJECTIVE: To develop a new patient-reported outcome measure for progressive supranuclear palsy (PSP) and to test its psychometric properties. METHODS: First, the authors generated a pool of potential scale items from in-depth patient interviews. Second, the authors these items, in the form of a questionnaire, to a sample of people with PSP and traditional psychometric methods were used to develop a rating scale satisfying standard criteria for reliability and validity.Third, the authors examined the psychometric properties of the rating scale in a second sample.RESULTS: In stage 1, a pool of 87 items was generated from 27 patient interviews. In stage 2, a scale with two subscales (physical, 22 items; mental, 23 items), satisfying standard criteria for reliability and validity, was developed from the response data of 225 patients with PSP. stage 3, the scale was examined in 188 people with PSP. Missing data were low, scores in both subscales were evenly distributed, floor and ceiling effects wer Validity was supported by the interscale intercorrelation (0.60), factor analysis, and the magnitude and pattern of correlations with four other rating scales, disease severity , and disease duration. The psychometric properties of the new scale were similar in the United Kingdom and North America, and in clinic-and community-based samples studied. CONCLUSIONS: The Progressive Supranuclear Palsy Quality of Life scale (PSP-QoL) may be a helpful patient-reported scale for clinical trials and studies in PSP.